The role and therapeutic potential of 5-HT-moduline in psychiatry

Seminars in Clinical Neuropsychiatry

Volumn 8, Issue 2, 2003, Pages 137-146

  Moret, Chantal ^a   Grimaldi, Brigitte ^b   Massot, Olivier ^b   Fillion, Gilles ^b  

^a NeuroBiz Consulting and Communication   (France)

^b Neuromoduline Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; 4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; GLUTAMIC ACID; LEUCYLSERYLALANYLLEUCINE; LEUCYLSERYLALANYLLEUCINE INHIBITOR; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PROTEIN INHIBITOR; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; 5-HT-MODULINE; DOPAMINE; NEUROPEPTIDE; OLIGOPEPTIDE;

ALZHEIMER DISEASE; ANXIETY; BEHAVIOR; BIOCHEMISTRY; CONFORMATIONAL TRANSITION; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; GABAERGIC TRANSMISSION; HUMAN; IMMOBILIZATION STRESS; MAZE TEST; MODEL; NEUROBIOLOGY; NONHUMAN; OBSESSION; OPEN FIELD BEHAVIOR; PROTEIN CONFORMATION; PROTEIN MODIFICATION; PROTEIN STABILITY; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SOCIAL INTERACTION; STRESS; TRAINING; TRANQUILIZING ACTIVITY; MENTAL DISEASE; METABOLISM;

ANTIDEPRESSIVE AGENTS; CORPUS STRIATUM; DOPAMINE; HUMANS; MENTAL DISORDERS; NEUROPEPTIDES; OLIGOPEPTIDES; RECEPTORS, SEROTONIN;

EID: 0038239359     PISSN: 10843612     EISSN: None     Source Type: Journal    
DOI: 10.1053/scnp.2003.50013     Document Type: Review

References (65)

1. Twarog BM, Page IH: Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 175:157-161, 1953
2. Zifa E, Fillion G: 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401-458, 1992
3. Fillion G, Fillion MP: Modulation of affinity of postsynaptic serotonin receptors by antidepressant drugs. Nature 292:349-351, 1981
4. Descarries L, Audet MA, Doucet G, et al: Morphology of central serotonin neurons: brief review of quantified aspects of their distribution and ultrastructural relationships. Ann N Y Acad Sci 600:81-92, 1990
5. Baumgarten HG, Grozdanovic Z: Anatomy of central serotoninergic projection systems, in Baumgarten HG, Göthert M (eds): Serotoninergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer-Verlag, pp 41-89, 1997
6. Audet MA, Descarries L, Doucet G: Quantified regional and laminar distribution of the serotonin innervation in the anterior half of adult rat cerebral cortex. J Chem Neuroanat 2:29-44, 1989
7. Moukhles H, Bosler O, Bolam JP, et al: Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 76:1159-1171, 1997
8. Hoyer D, Clarke DE, Fozard JR, et al: International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203, 1994
9. Hoyer D, Hannon JP, Martin GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554, 2002
10. Bruinvels AT, Palacios JM, Hoyer D: Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 347:569-582, 1993
11. 1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404:1-12, 2000
12. 1B autoreceptors and heteroreceptors and 5-HT-moduline in CNS disorders. CNS Spectrums 3:50-58, 1998
13. Rousselle JC, Massot O, Delepierre M, et al: Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes. J Biol Chem 271:726-735, 1996
14. 1B/1D receptors. Mol Pharmacol 50:752-762, 1996
15. 1d receptors expressed in transfected cultured cells. Naunyn-Schmiedeberg's Arch Pharmacol 358:279-286, 1998
16. 1B receptors. Proc Natl Acad Sci USA 94:9899-9904, 1997
17. Cloëz-Tayarani I, Cardona A, Sarhan H, et al: Mapping of 5-HT-moduline binding sites in guinea-pig brain by film and digital autoradiography. Brain Res 798:311-315, 1998
18. Grimaldi B, Fillion MP, Bonnin A, et al: Immunocytochemical localization of neurons expressing 5-HT-moduline in the mouse brain. Neuropharmacology 36:1079-1087, 1997
19. De Graeff FG, Guimaraes FS, De Andrade TG, et al: Role of 5-HT in stress, anxiety and depression. Pharmacol Biochem Behav 54:129-141, 1996
20. 1B receptors in the rat. Neurosci Res 27:277-280, 1997
21. Ohashi S, Matsumoto M, Togashi H, et al: Effects of 5-HT-moduline, a novel endogenous peptide, on serotonin release in the prefrontal cortex of freely moving rats. Biogenic Amines 16:101-114, 2001
22. 3H]dopamine from rat striatal synaptososomes. Naunyn-Schmiedeberg's Arch Pharmacol 359:40-47, 1999
23. 1B auto and heteroreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 360:382-390, 1999
24. 1B receptor knock-out mice. Naunyn-Schmiedeberg's Arch Pharmacol 361:12-18, 2000
25. 1B/1D receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. Eur J Pharmacol 358:129-137, 1998
26. Francés H: New animal model of social behavioural deficit: reversal by drugs. Pharmacol Biochem Behav 31:467-470, 1988
27. Briley M, Chopin P, Moret C: Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology 101:187-189, 1990
28. Briley M, Chopin P: Is anxiety associated with a hyper- or hypo-serotonergic state?, in Palomo T, Archer T (eds): Strategies for Studying Brain Disorders, Depression, Anxiety and Drug Abuse Disorders, vol 1, Editorial Complutence. Madrid: Donoso Cortés, pp 197-209, 1994
29. Neumaier JF, Edwards E, Plotsky PM: 5-HT(1B) mrna regulation in two animal models of altered stress reactivity. Biol Psychiatry 51:902-908, 2002
30. 1B receptors in the rat brain. Eur J Pharmacol 294:531-540, 1995
31. Pei Q, Zetterstrom T, Fillenz M: Tail pinch-induced changes in the turnover and release of dopamine and 5-hydroxytryptamine in different brain regions of the rat. Neuroscience 35:133-138, 1990
32. Clement H-W, Schäfer F, Ruwe C, et al: Stress-induced changes of extracellular 5-hydroxyindoleacetic acid concentrations followed in the nucleus raphe dorsalis and the frontal cortex of the rat. Brain Res 614:117-124, 1993
33. Kawahara H, Yoshida M, Yokoo H, et al: Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett 162:81-84, 1993
34. Vahabzadeh A, Fillenz M: Comparison of stress-induced changes in noradrenergic and serotonergic neurons in the rat hippocampus using microdialysis. Eur J Neurosci 6:1205-1212, 1994
35. Funada M, Hara C: Differential effects of psychological stress on activation of the 5-hydroxytryptamine- and dopamine-containing neurons in the brain of freely moving rats. Brain Res 901:247-251, 2001
36. Fujino K, Yoshitake T, Inoue O, et al: Increased serotonin release in mice frontal cortex and hippocampus induced by acute physiological stressors. Neurosci Lett 320:91-95, 2002
37. Bonnin A, Grimaldi B, Fillion MP: Acute stress induces a differential increase of 5-HT-moduline (LSAL) tissue content in various rat brain areas. Brain Res 825:152-160, 1999
38. Gamaro GD, Xavier MH, Denardin JD, et al: The effects of acute and repeated restraint stress on the nociceptive response in rats. Physiol Behav 63:693-697, 1998
39. Pol O, Campmany L, Armario A: Inhibition of catecholamine synthesis with alpha-methyl-p-tyrosine apparently increases brain serotonergic activity in the rat: no influence of previous chronic immobilization stress. Pharmacol Biochem Behav 52:107-112, 1995
40. Richardson JS: Brain parts monoamines in the neuroendocrine mechanisms activated by immobilization stress in the rat. Int J Neurosci 23:57-67, 1984
41. 1B receptors in rat central nervous system: role of 5-HT-moduline. Naunyn-Schmiedeberg's Arch Pharmacol 361:600-604, 2000
42. Grimaldi B, Bonnin A, Fillion MP, et al: 5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience 93:1223-1225, 1999
43. 1B/D receptors, in Baumgarten HG, Göthert M (eds): Serotoninergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer-Verlag, pp 269-291, 1997
44. Birdsall NJ, Lazareno S, Popham A, et al: Multiple allosteric sites on muscarinic receptors. Life Sci 68:22-23, 2001
45. Briley M, Moret C: Antidepressant properties of specific serotonin-noradrenaline reuptake inhibitors, in Skolnick P (ed): Antidepressants: New Pharmacological Strategies. Totowa, NJ: Humana Press, 1997
46. Feighner JP, Boyer WF (eds): Selective Serotonin Re-uptake Inhibitors. Chichester, UK: Wiley, 1991
47. Briley M, Moret C: Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16:387-400, 1993
48. Zohar J, Zohar-Kadouch RC, Kindler S: Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 43:210-218, 1992
49. Pigott TA, L'Heureux F, Hill JL, et al: A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12:11-18, 1992
50. Dolberg TO, Iancu I, Sasson Y, et al: The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 19:129-147, 1996
51. Zohar J, Insel TR, Zohar-Kadouch RC, et al: Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiat 45:167-172, 1988
52. Dolberg OT, Sasson Y, Cohen R, et al: The relevance of behavioral probes in obsessive-compulsive disorder. Eur J Neuropsychopharmacol 5:161-162, 1995
53. Stein DJ, Van Heerden B, Wessels CJ, et al: Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry 23:1079-1099, 1999
54. 1D agonist sumatriptan. Eur Neuropsychopharmacol 8:325-328, 1998
55. 1B receptors mediating inhibition of acetylcholine release. Eur J Pharmacol 129:333-337, 1986
56. 3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin. Brain Res 704:153-166, 1995
57. 1D receptors. Ann N Y Acad Sci 600:168-181, 1990
58. 3H]GABA in human, but not in rabbit, neocortex. Neurosci Lett 209:210-214, 1996
59. 1D receptors. Br J Pharmacol 123:45-50, 1998
60. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152, 1999
61. Hartig PR: Molecular biology and transductional characteristics of 5-HT receptors, in Baumgarten HG, Göthert M (eds): Serotoninergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer-Verlag, pp 175-212, 1997
62. Bordi F, Ugolini A: Group I metabotropic glutamate receptors: implications for brain diseases. Prog Neurobiol 59:55-79, 1999
63. 1B receptor gene deletion, in Baumgarten HG, Göthert M (eds): Serotoninergic Neurons and 5-HT Receptors in the CNS. Berlin: Springer-Verlag, pp 351-365, 1997
64. 1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology 21:238-246, 1999
65. Scearce-Levie K, Chen JP, Gardner E, et al: 5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders. Ann N Y Acad Sci 868:701-715, 1999